Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
出版年份 2022 全文链接
标题
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
作者
关键词
-
出版物
Lancet Gastroenterology & Hepatology
Volume 7, Issue 3, Pages 219-229
出版商
Elsevier BV
发表日期
2022-01-20
DOI
10.1016/s2468-1253(21)00385-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
- (2022) Ahmed Omar Kaseb et al. Lancet Gastroenterology & Hepatology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- (2021) E. A. Rozeman et al. NATURE MEDICINE
- Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
- (2021) Ming Lei et al. CLINICAL CANCER RESEARCH
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
- (2021) P. Schmid et al. ANNALS OF ONCOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma
- (2020) David J. Pinato et al. HEPATOLOGY
- Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
- (2019) Jing Liu et al. OncoImmunology
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease
- (2019) Peter A. Szabo et al. Nature Communications
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology
- (2017) Sonja Gordic et al. JOURNAL OF HEPATOLOGY
- Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies
- (2017) Wenjun Zhang et al. LABORATORY INVESTIGATION
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
- (2017) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- Recurrence of Hepatocellular Cancer After Resection
- (2015) Parissa Tabrizian et al. ANNALS OF SURGERY
- Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?
- (2015) Marc-Antoine Allard et al. JOURNAL OF HEPATOLOGY
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Risk factors of post‐operative recurrence and adequate surgical approach to improve long‐term outcomes of hepatocellular carcinoma
- (2012) Junichi Shindoh et al. HPB
- Effects of pre-operative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: Implication of circulating cancer cells by detection of α-fetoprotein mRNA
- (2010) MASAHIRO MURAKAMI et al. Experimental and Therapeutic Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search